Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK3 | P49761 | 7/20 | 0.83 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.83 |
| ▸ | CLK2 | P49760 | 6/20 | 0.83 |
| ▸ | ITK | Q08881 | 9/20 | 0.63 |
| ▸ | WNT1 | P04628 | 3/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18485282 | 0.91 | DYRK1A (0.83) | CLK3DYRK1ACLK2ITKWNT1 | |
| SCHEMBL18447091 | 0.91 | DYRK1A (1.00) | CLK3DYRK1ACLK2ITKWNT1 | |
| SCHEMBL18481252 | 0.87 | DYRK1A (0.73) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL20423160 | 0.86 | CLK2 (0.62) | CLK3DYRK1ACLK2ITKWNT1 | |
| SCHEMBL20451175 | 0.85 | DYRK1A (0.70) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18446425 | 0.84 | DYRK1A (0.69) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18443696 | 0.83 | CLK2 (0.84) | CLK3DYRK1ACLK2ITKWNT1 | |
| SCHEMBL18446079 | 0.83 | DYRK1A (0.64) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18487449 | 0.82 | ITK (0.68) | CLK3DYRK1ACLK2ITKFGFR1 | |
| SCHEMBL18446229 | 0.82 | CLK3 (0.66) | CLK3DYRK1ACLK2WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | claimed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK3 573/4885DYRK1A 585/4885CLK2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.